Brunangelo Falini

Personal Information     

Date of Birth:    08/05/1951

City, State/Province, Country of Birth:    Perugia, Italy

Citizenship(s):    Italian

Language(s):    Italian, English

Education          

Date    Degree    Institution    Subject

1988    Specialist in Internal Medicine    University of Perugia, Italy   

1976    M.D. Summa Cum Laude    University of Perugia, Italy   

Appointments/Affiliations          

Dates    Title    Organization    City, State/Province    Country

2001    Full Professor of Hematology    University of Perugia    Perugia    Italy

1992-2000    Associate Professor of Hematology    University of Perugia    Perugia    Italy

1990-Present    Head, Hematopathology Section    University of Perugia, Institute of Hematology    Perugia    Italy

1989-1990    Visiting Professor, Dept. Pathology    Free University of Berlin    Berlin    Germany

1982-1984    Research Fellow, Dept. Hematology    John Radcliffe Hospital    Oxford    England

1980-1981    Research Fellow, Dept. Pathology    University of Southern California    Los Angeles    United States

1976-1979    Intern, Institute of Internal Medicine    University of Perugia    Perugia    Italy

Honors/Awards          

Date    Name    Description

1998-Present    Member    European Bone Marrow Working Group

1997-2000    Member, Scientific Committee    Italian Association for Cancer Research

1997    Member, Clinical Advisory Committee    WHO Classification of Hematopoietic and Lymphoid Tumors

1992-Present    Member    International Lymphoma Study Group

1982-1984    Fellow    Leukemia Research Fund

1980-1981    Fellow    NATO

Memberships          

Dates    Organization    Position

2000-Present    Italian Society of ExperimentalHematology    Vice President

1998-Present    European Bone Marrow Working Group    Member

1992-Present    International Lymphoma Study Group    Member

1980-Present    Italian Society of Hematology    Member

Research Interests          

Field of Expertise &

Research Interests:    Classification and imunohistochemistry of lymphomas, ALK-positive anaplastic large cell lymphomas, immunotherapy of Hodgkin’s disease, generation of monoclonal antibodies against proteins associated to genetic lesions (PML, BCL6, MUM1/IRF4, ALK, NPM, MLF1, IRTA1) and use for the study of leukemias and lymphomas.